Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-05-17 16:50:45   浏览:9986   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载

昆明市人民政府关于加强勤工俭学经济活动管理的暂行规定

云南省昆明市人民政府


昆明市人民政府关于加强勤工俭学经济活动管理的暂行规定
 (1986年5月13日 昆政发〔1986〕99号)



第一章 总则





  第一条 为保证我市勤工俭学经济活动健康、顺利地发展,根据国务院国发〔1983〕25号文件批转《关于进一步开展勤工俭学活动的请示》和《全国中小学勤工俭学暂行工作条例》的精神,结合我市的实际情况,特制定本规定。


  第二条 我市各级各类学校和教育事业单位,在保证完成国家下达的计划任务和维护正常的教学秩序的前提下,从有利于提高教育质量、促进教育体制改革的需要出发,可根据本单位的实际,开展下列经济活动:
  1、中等专业学校和职业学校可开办各种为专业服务的工厂 、农场 、商店、服务部等,为培养各类专业人员提供技术教育实习基地,使学生能掌握一技之长,做好就业前准备。
  2、中小学校一般不搞纯商业经营,但可以结合安排富余人员,开展商业、服务业等多种形式的勤工俭学经济活动,把校办企业办成学生的生产劳动基地,对学生进行劳动观点教育和劳动技能训练。
  3、教育系统主管勤工俭学的部门,以及根据需要成立的专业公司,可兴办为教学和社会生产服务的企业。


  第三条 各级各类学校或各级教学服务公司兴办各种各种工商服务企业,必须按隶属关系经市县(区)教育主管部门审批,当地工商行政管理部门核发工商执照后,方可从事生产或经营活动。并应按税务部门的规定缴纳税收。其中,凡生产教学设备并在教育系统内部销售的校办工厂、以及各职业学校,中小学校校办企业,若纳税有困难,应按税收管理体制的规定,报经税务部门批准后,予以减免。但减免的税款只能用于扩大再生产,不得用于分配。


  第四条 各级各类学校开展勤工俭学经济活动,一般不准占用学校(单位)的房舍、场地,确需占用少量的,应在不影响教学事业发展的前提下,由学校(单位)继往开来规划,并报上级主管部门批准。
  严禁将学校的房舍、场地出租给外系统的单位经商办企业,已出租的,要限期收回。


  第五条 学校与其它国营、集体企业联合兴办工商服务企业,须经主管部门批准并坚持以下原则:
  1、不改变双方体制。
  2、共同管理,互利互惠。
  3、合同协议必须经有关部门公证。
  4、严格划分收益分配,按规定经批准减免税收的仅指校方部分,对方应按国家规定照章纳税。
  5、严禁以联营联办为名,变相出租房舍、场地或帐户。


  第六条 各级各类学校在开展勤工俭学活动中,要明确指导思想,注意社会效益,加强法制观念,遵纪守法、严禁出卖帐户、买空卖空、倒买倒卖、走私贩私、套购国家紧缺物资、行贿受贿和超越范围经营。

第二章 生产经营





  第七条 各级各类学校为开展勤工俭学经济活动所兴办的各种工商服务企业,经有关部门审核批准后,可定为集体所有制企业。


  第八条 校办工商服务企业与教育事业单位应分开管理,实行独立经济核算,自负盈亏。


  第九条 校办企业有权根据国家的政策规定,制定与本企业相适应的经营管理制度和生产经营方式;有权根据教需要和市场变化及明调整生产项目;有权利用企业的自有资金进行技术设备改造。


  第十条 有条件的企业,厂长(经理)可由民主选举产生,报主管部门认可;不具备选举条件的企业、厂长(经理)由主办单位任免,报主管部门备案。厂长(经理)有权提出厂级领导干部的候选人名单,报请上级主管部门批准;有权任聘副厂长(经理)以下的干部,但应报主办和主管单位备案。
  除固定职工外,企业有权根据生产的需要决定临时合同工的招聘、辞退及确定其劳动报酬,但不允许从社会或外单位雇请人员承包经营企业。


  第十一条 企业有权根据国家规定,确定企业内部的经济责任制和分配办法。
第三章 劳动工资





  第十二条 校办工商服务企业,必须坚持兼顾国家、集体、个人三者利益和按劳分配的原则,切实做好收益分配。其收益分配办法,必须执行国家有关规定并报主管单位审核。


  第十三条 企业创利(包括免征的工商所得税,能源交通重点建设基金等部分),除按规定上缴主办单位作为改善办学条件的基金外,应视企业不同情况,上交3%~5%给主管部门作为生产发展互助基金,其余留给企业。
  企业留得的50%~60%作为生产发展基金,其余(不包括减免税收部分)作为公益金、奖励基金。用于个人的奖金(包括各种非统一规定的补贴),必须执行国家规定并报主管部门批准。


  第十四条 为有得于考核企业的实绩和测算奖金控制总额,校办企业职工的月平均标准工资暂定为80元(包括各类补贴),低于80元的,以80元为基数计算奖金税。


  第十五条 根据各企业的不同情况,可选择以下不同的分配形式,报经主管单位批准后执行。
  1、实行基本工资加奖励的企业,其奖金可按每人年均二个月的基本工资计处成本。
  2、实行利奖挂勾的企业,以上年度创利为基数,按利润增长幅度确定奖金比例上下浮动。发放奖金超过四个月标准工资的,按财政部〔1985〕财税字316号《集体企业奖金税暂行规定实施办法》的规定缴纳奖金税。
  3、实行基本工资加浮动工资的企业,其浮动工资应控制在企业平均工资的50%以内。
  4、实行全尝工资、计件工资和提成工资的企业,应确定合理的定额单价,若个人所得部分超过标准工资总额和核定的奖金时,按规定开征奖金税。


  第十六条 教育事业编制的教职工调入校办企业工作,其工资计入企业成本,本人工资收入可与本企业职工相似工资对待,也可以按原工资标准计算。


  第十七条 校办工商服务企业的生产经营活动,原则上不宜实行个人承包,也不宜实行全包全奖,包超全部归个人的办法。


  第十八条 从一九八六年起,各校办工商服务企业,应在税前提取基本工资总额20%的福利基金,专户专存或参加社会保险。用于职工年老退休、丧失劳动力时的劳保享受,以及死亡丧葬抚恤等。

第四章 财务管理制度





  第十九条 各校办工商服务企业,应按《会计法》及有关规定,建立健全财会制度,要求做到:
  1、认真执行独立经济核算,自负盈亏的管理制度。
  2、必须设置与工作相适应的专(兼)职财务人员(财务人员的任免,需经主管单位考核和认可)。对兼职财务人员可根据工作量给予适当补贴。
  3、财务人员应切实履行自己的职责,坚持原则,坚持制度,发挥财会工作的监督保证作用。
  4、主管单位应组织财务人员定期检查、研究企业的财务工作,加强企业财务管理。

第五章 组织领导





  第二十条 各级各类学校开展勤工俭学经济活动而兴办的工商服务企业,学校为其主办单位,市、县(区)教育主管部门的专管机构为其主管单位。


  第二十一条 主办单位的职责是:
  1、为企业筹集和提供开办的必要资金、设备和场地。
  2、确定企业的生产经营方向,审定企业的发展规划。
  3、负责监督管理企业的生产经营活动,帮助企业解决生产经营活动中存在的问题。
  4、指导企业建立健全各项规章制度,监督检查企业执行党的方针政策和上级有关规定的情况。
  5、协助企业搞好职工的思想政治工作。


  第二十二条 主管单位的职责是:
  1、宣传、贯彻执行党和政府的有关方针政策,拟定相应的规章制度,组织领导校办企业开展好生产经营活动。
  2、负责制定和实施勤工俭学经济活动的长远规划和年度计划,进行财务监督和检查,汇总统计报表和办理日常事务。
  3、代表所属校办企业与有关部门进行业务联系、疏通校办企业产供销渠道和解决其它有关问题。
  4、审核批准和监督检查校办企业劳动工资、奖金等收益的分配执行情况。
  5、负责调查研究,总结交流经验,推动勤工俭学经济活动的健康发展。

第六章 附则




  第二十三条 本规定报经市人民政府同意后,自公布之日起执行,过去有关文件若与本规定抵触,以本规定为准。


                          昆明市教育局
                          昆明市财政局
                          昆明市计委
                          昆明市经委
                          一九八六年五月十三日

关于印发《新疆维吾尔自治区国有资本保值增值考核试行办法》的通知

新疆维吾尔自治区人民政府办公厅


新政办〔2001〕126号

关于印发《新疆维吾尔自治区国有资本保值增值考核试行办法》的通知

伊犁哈萨克自治州,各州、市、县(市)人民政府,各行政公署,自治区人民政府各部门、各直属机构:
 《新疆维吾尔自治区国有资本保值增值考核试行办法》已经自治区人民政府同意,现印发给你们,请认真遵照执行。

二○○一年八月十三日
  
新疆维吾尔自治区国有资本保值增值考核试行办法

第一章 总  则
第一条 为加强国有资本监督管理,维护国家所有者权益,提高国有资本营运效绩,规范国有资本保值增值考核工作,制定本办法。
  第二条 国有资本保值增值考核,是指财政(国资)部门根据注册会计师(或财政部门认可的中介机构)审定的企业年度会计报表资料,依法对列入考核范围的国家投资企业在一定经营期间所占有、使用的国有资本保值、增值或减值结果进行核实确认,并运用规定的方法分析判断国有资本运营效果及所处行业水平,为实施企业考核工作提供准确的依据。
  第三条 本办法所称的国有资本,是指国家对企业各种形式的投资和投资所形成的收益,以及依法认定的国家所有者权益。对于国有独资企业或公司,其国有资本等于该企业的所有者权益;对于拥有国家投资的有限责任公司和其他具有多元投资主体的企业,国有资本是企业所有者权益中国家应享有的份额。
  第四条 国有资本保值增值考核对象为各级人民政府直接投资设立的国有企业、国有独资公司和国有控股公司。凡实行经营者年薪制、风险抵押、期权制、持股试点和工效挂钩等将考核结果与收入分配制度挂钩的企业,均应纳入国有资本保值增值的考核范围。
 
第二章 考核指标
  第五条 国有资本保值增值结果主要通过国有资本保值增值率反映,同时设置有关分析指标。
  第六条 国有资本保值增值率反映的是企业国有资本的运营效益与安全状况,其计算公式为:
  国有资本保值增值率=(年末国家所有者权益/年初国家所有者权益)×100%
  第七条 国有资本保值增值结果的分析指标为资本积累率、净资产收益率、总资产报酬率和不良资产比率。分析指标主要对企业资本运营水平和质量,以及国有资本保值增值实际完成情况进行分析和验证。其中:
资本积累率=(本年所有者权益增长额/年初所有者权益)×100%
  净资产收益率=(净利润/平均净资产)×100%
  总资产报酬率=〔(利润总额+利息支出)/平均资产总额〕×100%
  不良资产比率=(年末不良资产总额/年末资产总额)×100%
  第八条 国有资本保值增值率完成值的确定,需剔除考核期内客观及非正常经营因素(包括增值因素和减值因素)对企业年末国家所有者权益的影响。其中:
  (一)增值因素为:
  1.国家直接或追加投资增加的国有资本;
  2.政府无偿划入增加的国有资本;
  3.按国家规定进行资产重估(评估)增加的国有资本;
  4.按国家规定进行清产核资增加的国有资本;
  5.住房周转金转入增加的国有资本;
6.接受捐赠增加的国有资本;
7.按国家规定进行“债权转股权”增加的国有资本;
8.中央和地方政府确定的其他客观因素增加的国有资本。
(二)减值因素为:
1.经专项批准核减的国家资本;
2.政府无偿划出或分立核减的国有资本;
3.按国家规定进行资产重估(评估)核减的国有资本;
4.按国家规定进行清产核资核减的国有资本;
5.中央和地方政府确定的其他客观因素核减的国有资本。
  
第三章 保值增值考核方法
  第九条 各级人民政府直接投资的国有企业、国有独资公司和国有控股公司是保值增值考核的重点,纳入保值增值考核的具体企业名单由各级财政部门商同级经贸、组织人事、劳动保障部门及企业工委共同确定。保值增值考核一般以一个会计年度为计算期间,凡纳入保值增值考核范围的企业,其法定代表人年初要与财政(国资)部门签订本年度国有资本保值增值责任书,以上年度会计报表的国家所有者权益年末数为基数,确保国有资本保值增值责任。
  第十条 国有资本保值增值考核的确认结果,依据年初签订的本年度国有资本保值增值责任书中核定的国有资本保值增值率与国有资本保值增值率实际完成值、行业标准值对照后得出,包括完成情况和所处行业水平两部分内容。
  (一)国有资本保值增值率以年初核定的国有资本保值增值率为基本衡量尺度,国有资本保值增值率实际值达到100%为保值,超过100%为增值,不足100%为减值。
  (二)依据财政部颁布的国有资本保值增值标准值,通过各企业国有资本保值增值率实际值与国有资本保值增值标准值的对比,衡量企业国有资本保值增值实现程度及完成情况,并按优秀值、较好值、平均值、较低值和较差值五个档次,客观、公正、真实地判断企业国有资本保值增值的实现程度和所处行业水平。
  (三)被列入保值增值考核范围的企业,各级财政(国资)部门要对其保值增值结果逐户计算和确认,并出具确认意见,同时抄送同级经贸、组织人事、劳动保障、企业工委等部门。
  (四)对未列入考核范围的企业,其国有资本保值增值
  考核工作由各级政府授权有关部门依据本办法进行考核。
  第十一条 如国家对考核年度国有资本保值增值系数进行调整,国有资本保值增值率实际值应作相应调整。
  第十二条 财政(国资)部门在确认保值增值考核结果后,可根据政府对企业监管需要,运用分析指标对照其参考标准做深入分析,并在此基础上,出具国有资本保值增值确认文件。
  第十三条 亏损企业当年减亏或增亏,除计算和确认实际保值增值率外,还应计算其减亏或增亏幅度:
  减亏幅度=(上年亏损总额-当年亏损总额)/上年亏损总额×100%
  增亏幅度=(当年亏损总额-上年亏损总额)/上年亏损总额×100%
  对由盈转亏和由亏变盈企业,按上述办法计算和确认国有资本保值增值率,并在确认意见和确认文书中作说明。
  第十四条 年初或年末国家所有者权益为负值时,不计算保值增值率,只根据年初及年末国家所有者权益数额做出判断,对国家资本保值增值完成情况分以下几种情况,并要求考核部门在确认意见中作特别说明:
  (一)年初权益为负值,年末权益为正值时,完成情况视同为增值。
  (二)年初权益为正值,年末权益为负值时,完成情况视同为减值。
  (三)年初、年末权益均为负值,且年末权益大于年初权益的,完成情况视同为增值。
  (四)年初、年末权益均为负值,且年末权益小于年初权益的,完成情况视同为减值。

 第四章 确认程序和结果运用
  第十五条 按照国有资产国家所有、分级监管的原则,国有资本保值增值考核工作,具体由各级财政(国资)部门会同经贸、劳动保障、组织人事和企业工委等部门分级组织实施。
  第十六条 国有资本保值增值考核以一个会计年度为计算期间,并以经财政部门认可的中介机构的注册会计师审定的企业年度会计报表为计算依据。被考核企业应对上报的国有资本保值增值考核基础资料的真实性和完整性负责。
  第十七条 国有资本保值增值考核工作程序
(一)确定考核对象。考核部门在确定了考核对象后,通知被考核企业,并提出工作要求,签订国有资本保值增值责任书。
  (二)被考核企业报送考核资料。被确定为考核对象的企业在向财政(国资)部门报送企业年度会计报表的同时,报送本年度《国有资本保值增值计算表》、《国有资本保值增值结果确认表》,并附送会计师事务所审计报告(复印件),及企业当年国有资本保值增值完成情况和国家所有者权益客观因素增减事项的说明材料。其中客观因素增减事项应提供有关部门或机构的批复文件、证明文件的复印件。
  考核对象为企业集团的,应以集团合并会计报表中的国家所有者权益为考核依据。
  (三)财政(国资)部门收到被考核企业上报的材料后,应对以下内容进行详细审核,并根据确认结果和情况分析,出具明确的确认意见或确认文件。
  1.审核企业各项基础财务指标的真实性和完整性及考核口径的变动情况;
  2.审核各项客观因素对企业国家所有者权益的影响;
  3.计算国有资本保值增值率指标实际完成值;
  4.对照年初核定的国有资本保值增值率与财政部统一颁布的《国有资本保值增值标准值》,得出保值增值考核确认结果;
  5.考核部门在“国有资本保值增值结果确认表”上出具确认意见。
  (四)汇总报送考核结果。年度考核确认工作结束后,各级财政(国资)部门对本级企业的国有资本保值增值考核确认结果进行汇总分析,上报上一级财政(国资)部门,并提交同级政府及有关部门。
  第十八条 对已经实施国有资本金效绩评价的企业,可以以评价工作中确认的国有资本保值增值率为依据,进行保值、增值和减值分析判断,不再另行计算与确认。
  第十九条 财政(国资)部门应将对企业国有资本保值增值考核结果提交经贸、劳动保障、组织人事、企业工委等有关部门,作为进行宏观决策,制定年薪制、持股制、工资分配等收入分配制度和对经营者进行考核、奖惩、任免的重要依据。
  (一)将国有资本保值增值指标作为企业提取新增效益工资的否定指标,凡是未实现国有资本保值增值的,不得提取当年新增效益工资;
  (二)凡试行年薪制及对经营者收入分配制度进行改革的企业,均要将国有资本保值增值指标作为对经营者的考核内容;
  (三)对于因经营管理不善,造成国有资本连续减值并且减幅进一步扩大的企业,由考核确认部门提请政府予以警告并督促企业采取切实可行的整改措施;
  (四)将国有资本保值增值指标作为组织人事、企业工委等部门对经营者的业绩考核、奖惩的依据。
  (五)在进行国民经济结构调整和企业资产重组过程中,要充分考虑企业国有资本保值增值完成情况,促进国有资本向优势企业和行业转移,形成良性循环。

  第五章 附  则
第二十条 国有资本保值增值考核工作结束后,各级财政(国资)部门负责对本级企业的国有资本保值增值确认结果进行汇总分析,向本级政府报送年度国有资本保值增值考核情况报告,同时抄送经贸、劳动保障、组织人事、企业工委等部门和国有企业监管机构,并建立保值增值考核档案。
  第二十一条 具体的国有资本保值增值考核奖惩办法另行制定。
  第二十二条 对国有资本保值增值考核工作,凡与本办法有抵触的,以本办法为准。
  第二十三条 本办法由自治区财政厅负责解释。
  第二十四条 本办法自发布之日起执行。